nference and BeiGene Collaborate on B-Cell Cancer Research

Apr 18, 2025
nference and BeiGene have announced a collaboration to enhance research on B-cell cancers using AI technology, focusing on chronic lymphocytic leukemia and small lymphocytic lymphoma.

nference and BeiGene have announced a collaboration to advance research in B-cell cancers, specifically targeting chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This partnership, announced in a press release, will utilize nference's proprietary Agentic AI platform to analyze real-world data from over 700 patient charts. The goal is to identify treatment patterns and improve clinical practices for these malignancies, which affect lymphocytes, a type of white blood cell crucial to immune function. CLL is noted as the most common adult leukemia in the U.S., highlighting the importance of this research initiative.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.